Clinical Trials Directory

Trials / Completed

CompletedNCT02965261

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablet Under Fasting Conditions

An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE Study of Fluoxetine Tablets 20 mg [Torrent,India] Versus Sarafem 20 mg Tablet [ Warner Chilcott LLC, USA] in Healthy Subjects-Fasted Condition.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
26 (actual)
Sponsor
Torrent Pharmaceuticals Limited · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Subjects to compare the single dose bioavailability of Torrent's Fluoxetine Tablets 20 mg and Sarafem® 20 mg Tablets of Warner Chilcott LLC, USA. Dosing periods of studies were separated by a washout period of 35 days.

Detailed description

An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose Bioequivalence Study of Fluoxetine Tablets containing Fluoxetine 20 mg ( Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Sarafem® 20 mg Tablets containing Fluoxetine 20 mg (Reference , Warner Chilcott LLC, USA) in Healthy Human Volunteers Under Fasting Condition.

Conditions

Interventions

TypeNameDescription
DRUGTorrent's Fluoxetine Tablets
DRUGWarner Chilcott LLC Sarafem Tablets

Timeline

Start date
2013-11-01
Primary completion
2014-01-01
Completion
2014-01-01
First posted
2016-11-16
Last updated
2016-11-16

Source: ClinicalTrials.gov record NCT02965261. Inclusion in this directory is not an endorsement.